Full Breakdown
FDA Moves to Increase Estradiol Patch Supply Amid Rising Demand
9/4/2026, 4:42:25 AM
Core Event
On September 3, the U.S. Food and Drug Administration (FDA) announced that it is coordinating with all six U.S. manufacturers of estradiol transdermal patches to expand production and alleviate reported access difficulties. The agency has not formally declared a shortage, but women have been “pharmacy-hopping,” adjusting dosages, or switching brands in response to limited availability.
Background on Menopause Hormone Therapy
Estradiol patches deliver estrogen directly into the bloodstream to relieve common menopause symptoms such as hot flashes, mood swings, and sleep disturbances. More than 1 million U.S. women begin menopause each year. Demand for these patches rose after the FDA removed a longstanding boxed warning that highlighted risks of cardiovascular disease, breast cancer, and probable dementia.
Manufacturers Involved
Supply-Boost Measures
The FDA reported that manufacturers are adding production shifts, expanding capacity, increasing batch sizes, and installing specialized equipment and new manufacturing lines. A Sandoz spokesperson noted the complexity of hormone-replacement patches and confirmed that the company has allocated additional supplies for U.S. patients. Bayer indicated that a temporary constraint will affect one dose of its Climara patch until early 2027. Viatris told Reuters that it is adding a production line and seeking third-party partners to accelerate output, citing the slow-to-scale nature of the required equipment. Data from the American Society of Health-System Pharmacists show that patches from Sandoz, Viatris, Noven, and Zydus are currently listed as in shortage.
Implications for Women
Expanding manufacturing capacity aims to reduce the need for patients to switch therapies or endure gaps in treatment, thereby supporting more consistent symptom management during menopause. While the FDA has not designated an official shortage, the coordinated effort reflects concern that supply constraints could disrupt hormone-replacement therapy for a growing population of women.
